フォルボールエステルはメトトレキサート耐性マウス細胞の発生率を劇的に増加させる:腫瘍増殖の潜在的なメカニズムと関連性

関連する実験動画

Updated: May 5, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

A Varshavsky

|August 1, 1981

まとめ

12-O-テトラデカノイル-ホルボル-13-アセテート (TPA) のような腫瘍プロモーターは,遺伝子増幅を増加させることができます. TPAは,3T6細胞におけるメトトレキサート抵抗性の発生率を大きく高め,ダイヒドロフォラート還元酵素 (DHFR) 遺伝子増幅を促進します.

科学分野:

腫瘍学腫瘍学
分子生物学は分子生物学である.
遺伝学遺伝学とは

背景:

腫瘍プロモーターは,がんの発症を促進する薬である.
遺伝子増幅は,癌の進行における既知のメカニズムである.
遺伝子増幅を促進する腫瘍プロモーターの役割は完全に理解されていません.

研究の目的:

腫瘍プロモーターが遺伝子増幅を促進する可能性があるという仮説を検証する.
12-O-テトラデカノイル-ホルボル-13-アセテート (TPA) が遺伝子増幅に影響を与えるかどうかを判断する.
3T6細胞におけるメトトレキサート耐性に対するTPAの影響を定量化するために.

主な方法:

3T6細胞におけるメトトレキサート耐性に対する単段階の選択.
耐性細胞の発生率の比較,TPA曝露と非曝露の比較.
耐性クローンにおけるディヒドロフォラート還元酵素 (DHFR) 遺伝子複製数の定量化.

主要な成果:

TPAはメトトレキサート耐性3T6細胞の発生率を100倍まで増加させた.
TPA効果は,メトトレキサートと同時に添加されたときに観察されました.
DHFR遺伝子複製数は,レジスタントのクローンにおいて著しく増加し,メトトレキサート濃度と相関しており,選択中のTPAの存在とは関係ありません.

結論:

12-O-テトラデカノイル-ホルボル-13-アセテート (TPA) は,遺伝子増幅の強力な強化剤として作用します.
TPAは遺伝子増幅により,薬剤耐性細胞の頻度を大幅に増加させます.
これらの発見は,腫瘍プロモーターが遺伝子増幅を通じて癌の進行に寄与するメカニズムを示唆しています.

さらに関連する動画

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Published on: December 26, 2016

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers

Published on: September 26, 2019

関連する概念動画

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Mouse Models of Cancer Study

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...